Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab Consolidation After BCMA CAR-T for Relapsed/Refractory Multiple Myeloma
NCT06066346Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talquetamab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate up to 2 years. Started Sep 2023; status: recruiting.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06066346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066346.